USEFULNESS OF CEFIXIME IN URINARY TRACT INFECTION FUNDAMENTAL STUDY WITH IN VITRO MODEL OF URINARY BLADDER AND CLINICAL STUDY

概要

論文の詳細を見る
We investigated the usefulness of cefixime (CFIX), a new oral cephalosporin, in patients with UTI in fundamental and clinical studies and obtained the following results: 1. In a fundamental study using a bladder model, CFIX inhibited bacterial regrowth longer than the reference drug, cefaclor. 2. In healthy volunteers given an oral dose of 100mg of CFIX under fasting condition, the serum concentrations peaked at 0.81μg/ml 3 hours after dosing, with a half-life of 1.86 hours. CFIX concentrations in the 2-4-hr urine peaked at 32.4μg/ml and the urinary recovery at 24 hours was 20.2%. 3. The clinical effect of CFIX according to the criteria of UTI committee in Japan was excellent in all 6 patients with acute uncomplicated cystitis. In complicated UTI, 26 of the 30 patients could be evaluated: The clinical effect was excellent in 11; good in 1; and poor in 14; with an effectiveness rate of 46%. 4. All the strains isolated from patients with acute uncomplicated cystitis were eradicated and 21 of the 30 strains isolated from patients with chronic complicated UTI were eradicated. The bacteriological eradication rate was 70%. 5. No subjective side effects were seen in any of the patients. GPT and K increased slightly in one patient.
公益社団法人日本化学療法学会の論文